Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study

Trial Profile

Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 May 2016

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Alcoholic hepatitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov record.
    • 06 Jul 2015 Planned initiation date changed from 1 Jun 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
    • 06 Jul 2015 Planned number of patients changed from 240 to 268 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top